New immunotherapy combo shows promise in ovarian cancer fight
NCT ID NCT03249142
First seen Jan 06, 2026 · Last updated May 22, 2026 · Updated 21 times
Summary
This study tested whether adding immunotherapy drugs (durvalumab with or without tremelimumab) to standard chemotherapy before surgery is safe and feasible for people with advanced ovarian, fallopian tube, or primary peritoneal cancer. About 69 participants received these treatments before and after surgery. The main goal was to check for side effects and see if the approach is practical for future larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Eugene Marquis
Rennes, France
-
Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495, France
-
Groupe confluent
Nantes, 44202, France
-
Gustave Roussy
Villejuif, France
-
HEGP
Paris, France
-
Hôpital Cochin
Paris, France
-
ICM Val d'Aurelle
Montpellier, France
-
Institut Bergonié
Bordeaux, France
-
Institut René Godinot
Reims, France
-
Institut Ste Catherine
Avignon, France
-
Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, France
Conditions
Explore the condition pages connected to this study.